Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)
- Citation:
- Blood vol 130 (suppl 1) 1879
- Meeting Instance:
- ASH 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- AFT
- Endpoint:
- Secondary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3304
- Pharmas:
- Celgene, Takeda
- Grants:
- Corr. Author:
- Authors:
- Peter M. Voorhees Michael Morris Luciano J. Costa Reeves Brandi Nitya Nathwani Cesar Rodriguez Yana Lutska Laura Hydutsky Huiling Pei Jon Ukropec Ming Qi Thomas Lin Paul G Richardson
- Networks:
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: